“It's called GLP one receptor,” said Atul Malhotra, MD from the UC San Diego School of Medicine. It’s already FDA-approved to ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

Adults with obesity who used medication and received guidance on resistance training and nutrition lost substantially more ...

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become household names in recent ...

Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

A new daily pill that suppresses the appetite has been shown to help patients lose weight in clinical trials.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP ...